Guangzhou Bosi Tao

Guangzhou Bositau Biotechnology is a Chinese biotechnology company specializing in the discovery and development of innovative therapeutic antibodies. The company leverages a high-throughput screening platform to identify high-affinity monoclonal antibodies targeting validated and novel checkpoints in oncology and immunology. Bositau provides contract research services (CRO) focused on antibody engineering, lead optimization, and preclinical validation for global pharmaceutical partners. Their internal pipeline focuses on next-generation immune checkpoint inhibitors and metabolic disease treatments, aiming to provide cost-effective biologic solutions.